Akademik Veri Yönetim Sistemi
INDIAN JOURNAL OF CANCER, sa.2, ss.274-279, 2016 (SCI-Expanded)
BACKGROUND: We reviewed clinical characteristics, treatment outcomes, local and distant failure and prognostic factors in patients with salivary gland carcinoma treated with surgery and postoperative radiotherapy. MATERIALS AND METHODS: We retrospectively reviewed 75 patients with salivary gland cancer. 69 (% 92) patients had cancer of the parotid gland, 3 (% 4) patients had cancer of the submandibular gland and 3 (% 4) patients had cancer of the minor salivary gland. 4 patients underwent postoperative chemoradiotherapy and 71 patients underwent postoperative radiotherapy. Median radiotherapy dose was 60Gy (range, 30Gy to 69Gy). RESULTS: Median age was 59.6 +/- 17.9 (13-88) and the female/male ratio was 1/1.7. Median follow-up 52 months (2-228 months). The mean overall survival 69.2 +/- 8 (95% confidence interval[CI], 53.4-85.1) months. The 1-, 3-, 5- and 10-year overall survival rates were 79.8%, 53.2%, 37.4% and 22.8% respectively. The mean disease free survival 79.7 +/- 10 (95% CI, 60.1-99.3) months. The 1-, 3-, 5- and 10-year disaese free survival rates were 72.8%, 51.9%, 44.1% and 30.4% respectively. On multivariate analysis, the OS was significantly better for the female sex (hazard ratio[HR]: 3,0; 95% CI: 1.5-5.6; P=0.001), absence of lymph node involvement ([HR]: 3,0; 95% CI: 1.7-5.3; P=0.0001), lower tumor grade ([HR]: 25,7; 95% CI: 3.3-199.3; P=0.002), negativity of the surgical margin ([HR]: 2,3; 95% CI: 1.3-4.2; P=0.005), absence of lymphovasculer invasion ([HR]: 2,6; 95% CI: 1.5-4.6; P=0.001), absence of extracapsuler extension ([HR]: 6,5; 95% CI: 2.2-19.1; P=0.001), absence of perineural invasion ([HR]: 4,8; 95% CI: 2.6-8.7; P=0.0001) and <= 60Gy radiotherapy dose ([HR]: 3,1; 95% CI: 1.7-5.5; P=0.0001). They observed local recurrens in17 (23%) patients and distant metastasis in 33 (44%) patients. CONCLUSIONS: Employing existing standards of postoperative radiotherapy is a possible treatment that was found to be effective mainly in patients with salivary gland carcinomas.